AbbVie, Allergan, Roche, and Cel-Sci Lead Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring news from AbbVie, Roche, and Cel-Sci. Editor’s Note: This article is…

Teva To Sell Actavis’ UK, Ireland Assets and Operations for $761 Million
By

By
Teva Pharmaceutical Industries has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited, a generic pharmaceutical company and a subsidiary of…

Daiichi Sankyo in Antimalarial Drug Research Collaboration
By

By
Daiichi Sankyo has entered into a new joint research agreement with Medicines for Malaria Venture (MMV), a Geneva, Switzerland-based product development partnership for antimalarial drug research and development, for a…

Eisai, Eurofarma to Develop Anticancer Agent in Latin America
By

By
Eisai’s research subsidiary, Morphotek, a biotechnology company headquartered in Exton, Pennsylvania, has signed an exclusive licensing agreement with Eurofarma Laboratórios, a São Paulo, Brazil-based pharmaceutical company, to develop and commercialize…

AstraZeneca, Aralez in Pact for Beta-blocker
By

By
AstraZeneca has entered into an agreement with Aralez Pharmaceuticals Trading DAC, a subsidiary of Mississauga, Canada-based Aralez Pharmaceuticals, a specialty pharmaceutical company, for the rights to branded and authorized generic…

Sarepta, Summit Partner in Muscular Dystrophy Drug Pipeline
By

By
Sarepta Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company focused on RNA-targeted therapeutics, has formed a collaboration with Summit Therapeutics, an Oxfordshire, UK-based biopharmaceutical company, which grants Sarepta rights in Europe, Turkey, and…

Amgen, Nuevolution in Oncology and Neuroscience Pact
By

By
Amgen has formed a multiple-target research collaboration with Nuevolution, a Copenhagen, Denmark -based biotechnology company focused on small-molecule drug discovery, to develop and commercialize therapeutics in oncology and neuroscience. Nuevolution…

Daiichi Sankyo, AgonOx in Immuno-Oncology Pact
By

By
Daiichi Sankyo Company has entered into a strategic collaboration with AgonOx, a Portland, Oregan-based biotechnology company developing a pipeline of immunotherapy cancer drugs, to develop an undisclosed immuno-oncology target. Under…

Merrimack Cuts 22% of Workforce, CEO Resigns
By

By
Merrimack Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company, has announced a major corporate restructuring that includes a 22% reduction in its workforce and the elimination of more than $200 million in expected costs…

EMA to Review Samsung Bioepis’ Herceptin Biosimilar
By

By
The European Medicines Agency (EMA) has accepted for review a marketing authorization application from Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen, for SB3, a biosimilar candidate referencing…